Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma Unclassifiable
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Sonrotoclax

Snippet

Sponsor: BeOne Medicines | Conditions: Mature B-Cell Malignancies | Phase 1 | Status: ACTIVE_NOT_RECRUITING